title: Premature luteinization and in vitro fertilization outcome in gonadotropin/gonadotropin-releasing hormone antagonist cycles in women with polycystic ovary syndrome.
abstract: OBJECTIVE
  To determine the incidence of premature luteinization in patients with polycystic ovary syndrome (PCOS) undergoing controlled ovarian hyperstimulation (COH) with exogenous gonadotropin/GnRH antagonist (GnRH-a); to compare clinical outcomes in patients with and without premature luteinization.
  
  
  METHODS
  Retrospective case series.
  
  
  METHODS
  IVF clinic.
  
  
  METHODS
  Thirty-five treatment cycles in 30 patients with PCOS.
  
  
  METHODS
  Controlled ovarian hyperstimulation with gonadotropin/GnRH-a protocol.
  
  
  METHODS
  Premature luteinization defined as a P concentration of >/=1.3 ng/mL on the day of hCG administration; number of oocytes and two pronuclei (2PN) embryos; implantation and clinical pregnancy rates (PR).
  
  
  RESULTS
  The incidence of premature luteinization was 28%. Compared with those without premature luteinization, patients with premature luteinization had a higher number of oocytes retrieved (24.1 +/- 13.3 vs. 12.0 +/- 5.9) and greater number of mature oocytes (19.7 +/- 11.7 vs. 9.5 +/- 4.5), respectively. The number of good quality embryos and embryos transferred was not significantly different between groups. Although implantation rates (56% vs. 40%) and clinical PRs (36% vs. 30%) were higher in patients without premature luteinization, the differences were not statistically significant.
  
  
  CONCLUSIONS
  The patients with PCOS with premature luteinization had a higher number of oocytes retrieved and mature oocytes, and similar clinical PRs as patients with PCOS without premature luteinization.
authors.affiliation: Reproductive Science Center, Lexington, Massachusetts 02421, USA. ShimonSegal@AOL.com
authors.forename: Shimon
authors.initials: S
authors.lastname: Segal
authors.forename: Isaac
authors.initials: I
authors.lastname: Glatstein
authors.forename: Patricia
authors.initials: P
authors.lastname: McShane
authors.forename: Selen
authors.initials: S
authors.lastname: Hotamisligil
authors.forename: Diego
authors.initials: D
authors.lastname: Ezcurra
authors.forename: Ronald
authors.initials: R
authors.lastname: Carson
mesh_terms: D000328:Adult; D005260:Female; D005307:Fertilization in Vitro; D007987:Gonadotropin-Releasing Hormone / Q000037:antagonists & inhibitors*; D006801:Humans; D010053:Ovary / Q000187:drug effects* / Q000502:physiology; D011085:Polycystic Ovary Syndrome / Q000503:physiopathology*; D011247:Pregnancy; D018873:Pregnancy Rate; D011374:Progesterone / Q000097:blood*; D012189:Retrospective Studies
chemical_list: D007987:Gonadotropin-Releasing Hormone; D011374:Progesterone